Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 1
Table of contents:
Evaluation report part1 (pdf portfolio)
01 - Pre-Meeting Briefing prepared by NICE
02 - Submission from the technology manufacturer - Takeda
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 1
26 November 2014 (5.64 Mb 3 sec) |
This page was last updated: 25 November 2014